Peripheral blood plasma profiles of circulating microRNA expression were analyzed in patients with prostatic cancer and benign hyperplasia. In prostatic cancer, significant increase in hsa-miR-619-5p and hsa-miR-1184 microRNA expression and significant decrease in hsalet-7b-5p and hsa-let-7c-5p microRNA expression were observed. The role of the relationship between the microRNA expression and the activities and functions of host genes with introns encoding these microRNA is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. N. Khyazev, K. A. Fomicheva, K. M. Nyushko, A. D. Kaprin, B. Ya. Alekseev, and M. Yu. Shkurnikov, Molecular diagnosis of prostate cancer: Topical issues. Onkourologiya, No. 4, 14–22 (2014).
M. Yu. Skurnikov, Yu. A. Makarova, E. N. Knyazev, K. A. Fomicheva, K. M. Nyushko, E. K. Saribekyan, B. Ya. Alekseev, and A. D. Kaprin, Profile of microRNA in Blood Plasma of Healthy Humans. Bull. Exp. Biol. Med., 160, No. 5, 577–579 (2016).
S. Ambs, R. L. Prueitt, M. Yi, R. S. Hudson, T. M. Howe, F. Petrocca, T. A. Wallace, C. G. Liu, S. Volinia, G. A. Calin, H. G. Yfantis, R. M. Stephens, and C. M. Croce, Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res., 68, No. 15, 6162–6170.
G. F. Carvalhal, D. S. Smith, D. E. Mager, C. Ramos, and W. J. Catalona, Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J. Urol., 161, No. 3, 835–839 (1999).
Z. H. Chen, G. L. Zhang, H. R. Li, J. D. Luo, Z. X. Li, G. M. Chen, J. Yang, A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate, 72, No. 13, 1443–1452 (2012).
M. A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood, and G. A. Calin, MicroRNAs in body fluids – the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol., 8, No. 8, 467–477 (2011).
J. A. Makarova, M. U. Shkurnikov, A. A. Turchinovich, A. G. Tonevitsky, and A. I. Grigoriev, Circulating microRNAs. Biochemistry (Mosc.), 80, No. 9, 1117–1126 (2015).
Y. Matsuda, M. Hagio, and T. Ishiwata, Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J. Gastroenterol., 19, No. 1, 42–48 (2013).
K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela, and T. Visakorpi, MicroRNA expression profiling in prostate cancer. Cancer Res., 67, No. 13, 6130–6135 (2007).
Q. Ren, J. Liang, J. Wei, O. Basturk, J. Wang, G. Daniels, L. L. Gellert, Y. Li, Y. Shen, I. Osman, J. Zhao, J. Melamed, and P. Lee, Epithelial and stromal expression of miRNAs during prostate cancer progression. Am. J. Transl. Res., 6, No. 4, 329–339 (2014).
M. Schubert, M. Spahn, S. Kneitz, C. J. Scholz, S. Joniau, P. Stroebel, H. Riedmiller, and B. Kneitz, Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in highrisk prostate cancer. PLoS One, 8, No. 6, doi: 10.1371/journal.pone.0065064 (2013).
K. Takahashi, S. I. Kanno, and K. Mizuno, Activation of cytosolic Slingshot-1 phosphatase by gelsolin-generated soluble actinfilaments. Biochem. Biophys. Res. Commun., 454, No. 3, 471–477 (2014).
I. M. Thompson, D. K. Pauler, P. J Goodman., C. M. Tangen, M. S. Lucia, H. L. Parnes, L. M. Minasian, L. G. Ford, S. M. Lippman, E. D. Crawford, J. J. Crowley, and C. A. Coltman Jr. Prevalence of prostate cancer among men with a prostatespecific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med., 350, No. 22, 2239–2246 (2004).
Y. Wang, Y. Kuramitsu, T. Kitagawa, B. Baron, S. Yoshino, S. Maehara, Y. Maehara, M. Oka, and K. Nakamura, Cofilinphosphatase slingshot-1L (SSH1L) is over-expressed in pancreatic cancer (PC) and contributes to tumor cell migration. Cancer Lett., 360, No. 2, 171–176 (2015).
W. Xiao, Z. X. Bao, C. Y. Zhang, X. Y. Zhang, L. J. Shi, Z. T. Zhou, W. W. Jiang, Upregulation of miR-31* is negativelyassociated with recurrent/newly formed oralleukoplakia. PLoS One, 7, No. 6, doi: 10.1371/journal.pone.0038648 (2012).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 161, No. 1, pp. 124–127, January, 2016
Rights and permissions
About this article
Cite this article
Knyazev, E.N., Fomicheva, K.A., Mikhailenko, D.S. et al. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. Bull Exp Biol Med 161, 108–111 (2016). https://doi.org/10.1007/s10517-016-3357-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3357-7